Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: WTH001
MIFTS: 50

Withdrawal Disorder

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Withdrawal Disorder

About this section

MalaCards integrated aliases for Withdrawal Disorder:

Name: Withdrawal Disorder 12 15
Withdrawal Syndrome 56 15
Substance Withdrawal Syndrome 74

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060001
UMLS 74 C0038587
Sources

Summaries for Withdrawal Disorder

About this section
Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as withdrawal syndrome, is related to opiate dependence and neonatal abstinence syndrome, and has symptoms including seizures, opiate withdrawal symptoms and drug withdrawal symptoms. An important gene associated with Withdrawal Disorder is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Interleukin-4 and 13 signaling. The drugs Ethanol and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and t cells, and related phenotypes are behavior/neurological and homeostasis/metabolism

Sources

Related Diseases for Withdrawal Disorder

About this section

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 31.8 OPRD1 OPRK1 OPRM1 PDYN
2 neonatal abstinence syndrome 31.6 OPRD1 OPRK1 OPRM1
3 heroin dependence 31.5 OPRD1 OPRM1 PDYN
4 anxiety 29.8 CNR1 OPRL1 TSPO
5 opioid addiction 29.6 OPRD1 OPRK1 OPRM1
6 alcohol dependence 29.0 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
7 drug dependence 28.5 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
8 barbiturate dependence 11.3
9 nodular prostate 10.3 AR KLK3
10 cyclic vomiting syndrome 10.2 CNR1 OPRM1
11 androgenic alopecia 10.2 AR KLK3
12 prostate cancer 10.2
13 prostate cancer, hereditary, 8 10.2
14 prostate cancer, hereditary, 6 10.2
15 prostatic hyperplasia, benign 10.2 AR KLK3
16 uremic pruritus 10.2 CNR1 OPRK1
17 prostatic hypertrophy 10.2 AR KLK3
18 cystitis cystica 10.1 AR KLK3
19 drug-induced mental disorder 10.1 CNR1 FOS
20 drug psychosis 10.0 CNR1 FOS
21 opioid abuse 10.0 OPRL1 OPRM1 PDYN
22 separation anxiety disorder 10.0 OPRM1 TSPO
23 subacute delirium 9.9
24 depression 9.9
25 amnestic disorder 9.9 CNR1 PDYN TSPO
26 substance dependence 9.9 CNR1 OPRD1 OPRK1 OPRM1
27 morphine dependence 9.9 FOS OPRD1 OPRK1 OPRM1
28 leukemia 9.9
29 cocaine dependence 9.9 OPRD1 OPRK1 OPRM1 PDYN
30 motion sickness 9.8 ADRA2A FOS
31 alcohol abuse 9.8
32 myeloid leukemia 9.8
33 specific developmental disorder 9.8 CNR1 OPRL1 OPRM1 PDYN
34 hypertension, essential 9.7
35 parkinson disease, late-onset 9.7
36 liver cirrhosis 9.7
37 restless legs syndrome 9.7
38 neuroleptic malignant syndrome 9.7
39 status epilepticus 9.7
40 rere-related disorders 9.7
41 spasticity 9.7
42 disease of mental health 9.7 CNR1 FOS OPRM1 PDYN
43 esophageal cancer 9.6
44 rheumatoid arthritis 9.6
45 schizophrenia 9.6
46 cystic fibrosis 9.6
47 myelofibrosis 9.6
48 taqi polymorphism 9.6
49 leukemia, acute lymphoblastic 9.6
50 gastric cancer 9.6

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder
Sources

Symptoms & Phenotypes for Withdrawal Disorder

About this section

UMLS symptoms related to Withdrawal Disorder:


seizures, opiate withdrawal symptoms, drug withdrawal symptoms, withdrawal symptoms

MGI Mouse Phenotypes related to Withdrawal Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 ADRA2A AR CNR1 FOS OPRD1 OPRK1
2 homeostasis/metabolism MP:0005376 10.06 ADRA2A AR CNR1 FOS NPL OPRD1
3 integument MP:0010771 9.86 AR CNR1 FOS OPRD1 OPRK1 OPRL1
4 nervous system MP:0003631 9.81 ADRA2A AR CNR1 FOS OPRD1 OPRK1
5 normal MP:0002873 9.5 ADRA2A AR CNR1 FOS OPRL1 OPRM1
6 reproductive system MP:0005389 9.17 AR CNR1 FOS NPL OPRK1 OPRM1
Sources

Drugs & Therapeutics for Withdrawal Disorder

About this section

Drugs for Withdrawal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
2
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
3
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 1 113775-47-6 5311068 68602
4
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 52485-79-7 644073 40400
6
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3 249296-44-4 5310966
7
Oxazepam Approved Phase 4 604-75-1 4616
8
Sodium oxybate Approved Phase 4 502-85-2 5360545
9
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 439-14-5 3016
10
Lorazepam Approved Phase 4,Phase 2,Not Applicable 846-49-1 3958
11
Lofexidine Approved, Investigational Phase 4,Phase 3,Phase 1 31036-80-3 30668
12
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 89594 942
13
Haloperidol Approved Phase 4 52-86-8 3559
14
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
15
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
16
Chlordiazepoxide Approved, Illicit, Investigational Phase 4,Phase 3 58-25-3 2712
17
Nitric Oxide Approved Phase 4 10102-43-9 145068
18
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
19
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
20
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
21
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
22
Dopamine Approved Phase 4,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
23
Memantine Approved, Investigational Phase 4 19982-08-2 4054
24
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
25
Abatacept Approved Phase 4,Phase 3 332348-12-6 10237
26
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 5284616 6436030
27
Mycophenolic acid Approved Phase 4,Phase 2,Not Applicable 24280-93-1 446541
28
Loperamide Approved Phase 4 53179-11-6 3955
29
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
30
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
31
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
32
Tetrabenazine Approved, Investigational Phase 4,Phase 3 58-46-8 6018
33
Everolimus Approved Phase 4,Phase 1,Phase 2,Not Applicable 159351-69-6 70789204 6442177
34
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
35
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
36
Phenobarbital Approved, Investigational Phase 4,Not Applicable 50-06-6 4763
37
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 73-31-4 896
38
Calcium Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 7440-70-2 271
39
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
40 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Not Applicable
42 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Anti-Infective Agents, Local Phase 4,Phase 3,Phase 2,Not Applicable
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
47 Excitatory Amino Acids Phase 4,Phase 2,Not Applicable
48 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antimanic Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 228)
# Name Status NCT ID Phase Drugs
1 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
2 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
3 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
4 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
5 Treatment of Alcohol Withdrawal in Hospital Patients Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
6 Lofexidine for Inpatient Opiate Detox in Singapore Completed NCT01675648 Phase 4 Lofexidine;Diazepam;Placebo for Lofexidine;Placebo for Diazepam
7 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4 Nicotine;Placebo
8 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU Completed NCT02496650 Phase 4 Dexmedetomidine
9 Nicotine Replacement Therapy in the Intensive Care Unit Completed NCT01362959 Phase 4 Transdermal nicotine patch
10 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
11 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
12 Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Completed NCT01573052 Phase 4 Chlordiazepoxide;Gabapentin
13 Nicotine Patch for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
14 Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients Completed NCT01501929 Phase 4 Metoprolol succinate;Nebivolol
15 Buprenorphine in the Emergency Department Completed NCT03174067 Phase 4 Buprenorphine;Clonidine
16 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
17 Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers Completed NCT01048944 Phase 4 Bupropion SR;Nicotine Patch;Placebo Patch and Placebo Pill
18 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
19 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
20 Gabapentin for Alcohol Withdrawal Syndrome Recruiting NCT03012815 Phase 4 Gabapentin;Benzodiazepines;Divalproex Sodium
21 Pregabalin for Opiate Withdrawal Syndrome Recruiting NCT03017430 Phase 4 Pregabalin;Clonidine;Doxylamin;Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
22 Assessment of Valproate on Ethanol Withdrawal Recruiting NCT03235531 Phase 4 Valproate;Lorazepam
23 Varenicline OTC Trial on Efficacy and Safety Recruiting NCT03557294 Phase 4 1.0mg Varenicline b.i.d.;0.5mg Varenicline b.i.d.;0.0mg placebo Varenicline b.i.d.
24 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Recruiting NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
25 Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine Not yet recruiting NCT03788889 Phase 4 Ketamine;Phenobarbital;Lorazepam;Placebo A;Placebo B
26 Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients Not yet recruiting NCT03397212 Phase 4
27 Precision Medicine Offers Belatacept Monotherapy Not yet recruiting NCT02939365 Phase 4 Belatacept
28 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
29 Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant Terminated NCT00148252 Phase 4 Mycophenolate mofetil withdrawal;Cyclosporione A withdrawal
30 Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms Terminated NCT02423018 Phase 4 Pregabalin;Placebo
31 Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids. Unknown status NCT01793480 Phase 3 Methadone
32 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
33 Smoking Cessation & Opioid Dependence Treatment Integration Unknown status NCT02854800 Phase 2, Phase 3 varenicline
34 Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome Completed NCT00146471 Phase 3 Levetiracetam;Placebo
35 Outpatient Treatment of Alcohol Withdrawal Syndrome Completed NCT00136617 Phase 3 chlordiazepoxide
36 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Completed NCT00980044 Phase 2, Phase 3 Tramadol;Placebo
37 Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
38 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3 Buprenorphine/naloxone
39 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3 Buprenorphine/naloxone
40 Open-Label, Safety Study of Lofexidine Completed NCT02363998 Phase 3 Lofexidine
41 Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis Completed NCT01142726 Phase 3 Abatacept;Methotrexate;Abatacept placebo;Methotrexate placebo
42 Effects of Somatostatin on Liver in ADPKD Completed NCT02119052 Phase 2, Phase 3 octeotride;placebo
43 The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia Completed NCT00164775 Phase 3 Imipramine;Placebo
44 A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects Completed NCT02391571 Phase 3 Oxycodone/Naltrexone Capsules;Oxycodone;Placebo
45 Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal Completed NCT00664404 Phase 3
46 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed NCT02161562 Phase 3 omalizumab;omalizumab
47 Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. Completed NCT00368745 Phase 3 Pregabalin;Placebo
48 MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA) Recruiting NCT03033823 Phase 3 Magnesium;Placebo Oral Tablet
49 Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU Recruiting NCT02723383 Phase 3 BACLOFEN;PLACEBO
50 A Study to Evaluate the Safety and Tolerability of Long-term Therapy With TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo

Search NIH Clinical Center for Withdrawal Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :
Sources

Genetic Tests for Withdrawal Disorder

About this section
Sources

Anatomical Context for Withdrawal Disorder

About this section

MalaCards organs/tissues related to Withdrawal Disorder:

42
Brain, Testes, T Cells, Cortex, Thyroid, Endothelial, Myeloid
Sources

Publications for Withdrawal Disorder

About this section

Articles related to Withdrawal Disorder:

(show top 50) (show all 1121)
# Title Authors Year
1
Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions. ( 30334926 )
2019
2
Alcohol Use Disorder and Alcohol Withdrawal Syndrome in Vietnamese Hospitalized Patients. ( 30660599 )
2019
3
In utero exposure to norbuprenorphine, a major metabolite of buprenorphine, induces fetal opioid dependence and leads to neonatal opioid withdrawal syndrome. ( 31028107 )
2019
4
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. ( 30361043 )
2019
5
Clinical considerations about opioid withdrawal syndrome. ( 30806586 )
2019
6
Treatment of Alcohol Withdrawal Syndrome. ( 30824508 )
2019
7
In Reply to "Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol". ( 30824510 )
2019
8
Predictive factors for abiraterone withdrawal syndrome. ( 31060755 )
2019
9
Placental aromatase expression decreased in severe neonatal opioid withdrawal syndrome. ( 31092079 )
2019
10
Malignant deep brain stimulator withdrawal syndrome. ( 31092485 )
2019
11
Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model. ( 31020587 )
2019
12
Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. ( 30937668 )
2019
13
Correlation between the epigenetic modification of histone H3K9 acetylation of NR2B gene promoter in rat hippocampus and ethanol withdrawal syndrome. ( 30903572 )
2019
14
Alcohol withdrawal syndrome management: Is there anything new? ( 30853380 )
2019
15
Effect of intranasal oxytocin on alcohol withdrawal syndrome: A randomized placebo-controlled double-blind clinical trial. ( 30784955 )
2019
16
Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. ( 30745655 )
2019
17
Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome. ( 30729859 )
2019
18
Alcohol Withdrawal Syndrome: Improving Recognition and Treatment in the Emergency Department. ( 30702536 )
2019
19
The nuclear receptor Shp regulates morphine withdrawal syndrome via modulation of Ugt2b expression in mice. ( 30689982 )
2019
20
Evaluating the Use of Phenobarbital for the Management of Alcohol Withdrawal Syndrome in Psychiatric Inpatients. ( 30630378 )
2019
21
Recognition, Assessment, and Pharmacotherapeutic Treatment of Alcohol Withdrawal Syndrome in the Intensive Care Unit. ( 30507660 )
2019
22
Symptom-triggered therapy for assessment and management of alcohol withdrawal syndrome in the emergency department short-stay clinical decision unit. ( 30282630 )
2019
23
Parent's experiences of their child's withdrawal syndrome: a driver for reciprocal nurse-parent partnership in withdrawal assessment. ( 30224222 )
2019
24
Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol. ( 30187438 )
2019
25
Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. ( 29079142 )
2018
26
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. ( 30498775 )
2018
27
Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. ( 29898114 )
2018
28
Psychopharmacological effects and safety of styryl-2-pyrones and dihydrostyryl-2-pyrones-rich fraction from Polygala sabulosa: absence of withdrawal syndrome and tolerance to anxiolytic-like and anticonvulsant effects. ( 29956326 )
2018
29
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. ( 28971898 )
2018
30
A Practical Approach to Neonatal Opiate Withdrawal Syndrome. ( 29100261 )
2018
31
Ketogenic Diet Suppresses Alcohol Withdrawal Syndrome in Rats. ( 29160944 )
2018
32
Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence. ( 29219048 )
2018
33
Incidence rates of admissions associated with alcohol withdrawal syndrome in Spain: Analysis of minimum basic data set 1999-2010. ( 29274671 )
2018
34
Is medical treatment of Alcohol Withdrawal Syndrome a Stag Hunt? Challenges and opportunities in managing risk and uncertainty in addiction cessation. ( 29317849 )
2018
35
Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms. ( 29434990 )
2018
36
Blood biomarkers of Hikikomori, a severe social withdrawal syndrome. ( 29440704 )
2018
37
Baclofen and the Alcohol Withdrawal Syndrome-A Short Review. ( 30723432 )
2018
38
The Prophylactic and Therapeutic Effects of Saffron Extract and Crocin on Ethanol Withdrawal Syndrome in Mice. ( 30652054 )
2018
39
Care-by-parent model as a tool for reduction in neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero. ( 30563376 )
2018
40
Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age. ( 30554024 )
2018
41
Impact of In-utero Exposure to Selective Serotonin Reuptake Inhibitors and Opioids on Neonatal Opioid Withdrawal Syndrome. ( 30489344 )
2018
42
Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the emergency department. ( 30414743 )
2018
43
Lofexidine for Treating Opioid Withdrawal Syndrome in Palliative Care Patients. ( 30410274 )
2018
44
Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol. ( 30385536 )
2018
45
Attenuation of Morphine Withdrawal Syndrome by Prosopis Farcta Extract and Its Bioactive Component Luteolin in Comparison with Clonidine in Rats. ( 30297685 )
2018
46
Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic Review. ( 30167704 )
2018
47
Systematic review of acupuncture for the treatment of alcohol withdrawal syndrome. ( 30030272 )
2018
48
Life-threatening DBS withdrawal syndrome in Parkinson's disease can be treated with early reimplantation. ( 30007510 )
2018
49
A subtype-specific neuropeptide FF receptor antagonist attenuates morphine and nicotine withdrawal syndrome in the rat. ( 29981879 )
2018
50
Correlation Between mMINDS and CIWA-Ar Scoring Tools in Patients With Alcohol Withdrawal Syndrome. ( 29961663 )
2018
Sources

Variations for Withdrawal Disorder

About this section
Sources

Expression for Withdrawal Disorder

About this section
Search GEO for disease gene expression data for Withdrawal Disorder.
Sources

Pathways for Withdrawal Disorder

About this section

Pathways related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Peptide ligand-binding receptors 67
Show member pathways
 12.56 ADRA2A CNR1 GABRR3 OPRD1 OPRK1 OPRL1
2
Interleukin-4 and 13 signaling 67
11.39 FOS OPRD1 OPRM1
3
FOXA1 transcription factor network 1
Show member pathways
 10.79 AR FOS KLK3
4
Nongenotropic Androgen signaling 1
10.51 AR FOS
Sources

GO Terms for Withdrawal Disorder

About this section

Cellular components related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 ADRA2A CNR1 GABRR3 OPRD1 OPRK1 OPRL1
2 axon terminus GO:0043679 9.43 OPRD1 OPRK1 PDYN
3 integral component of synaptic vesicle membrane GO:0030285 9.4 OPRD1 OPRK1
4 dendrite membrane GO:0032590 9.37 OPRD1 OPRM1
5 spine apparatus GO:0097444 8.96 OPRD1 OPRM1
6 integral component of presynaptic membrane GO:0099056 8.92 CNR1 OPRD1 OPRK1 OPRM1
7 plasma membrane GO:0005886 10.02 ADRA2A AR CNR1 GABRR3 NISCH OPRD1

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.79 CNR1 FOS TSPO
2 response to lipopolysaccharide GO:0032496 9.77 CNR1 FOS OPRM1
3 response to ethanol GO:0045471 9.77 CNR1 OPRK1 OPRM1
4 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 CNR1 OPRD1 OPRM1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.71 OPRD1 OPRK1 OPRM1
6 sensory perception of pain GO:0019233 9.71 CNR1 OPRK1 OPRL1 OPRM1
7 response to cocaine GO:0042220 9.69 CNR1 OPRK1 OPRM1
8 response to morphine GO:0043278 9.65 CNR1 OPRK1 OPRM1
9 neuropeptide signaling pathway GO:0007218 9.65 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
10 response to progesterone GO:0032570 9.62 FOS TSPO
11 response to radiation GO:0009314 9.62 OPRK1 OPRM1
12 regulation of sensory perception of pain GO:0051930 9.62 OPRD1 OPRK1 OPRL1 OPRM1
13 negative regulation of blood pressure GO:0045776 9.61 CNR1 OPRL1
14 estrous cycle GO:0044849 9.61 OPRK1 OPRL1 OPRM1
15 regulation of synaptic transmission, GABAergic GO:0032228 9.58 CNR1 NISCH
16 regulation of systemic arterial blood pressure GO:0003073 9.58 AR KLK3
17 behavior GO:0007610 9.57 OPRK1 OPRL1
18 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.55 OPRL1 OPRM1
19 sensory perception GO:0007600 9.54 OPRK1 OPRL1 OPRM1
20 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.46 OPRK1 OPRM1
21 eating behavior GO:0042755 9.46 OPRD1 OPRK1 OPRL1 OPRM1
22 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.35 ADRA2A OPRD1 OPRK1 OPRL1 OPRM1
23 opioid receptor signaling pathway GO:0038003 8.92 OPRD1 OPRK1 OPRL1 OPRM1
24 signal transduction GO:0007165 10.13 ADRA2A AR CNR1 GABRR3 OPRD1 OPRK1
25 G protein-coupled receptor signaling pathway GO:0007186 10.04 ADRA2A CNR1 OPRD1 OPRK1 OPRL1 OPRM1

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.63 ADRA2A CNR1 OPRD1 OPRK1 OPRL1 OPRM1
2 receptor serine/threonine kinase binding GO:0033612 9.32 OPRD1 OPRK1
3 androgen binding GO:0005497 9.26 AR TSPO
4 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
5 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1
Sources

Sources for Withdrawal Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....